FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					_	1								1						
Name and Address of Reporting Person* Ratliff John D					<u>L</u>	2. Issuer Name and Ticker or Trading Symbol LABORATORY CORP OF AMERICA								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
						HOLDINGS [LH]								Director Officer (give title			Other (· .		
(Last) (First) (Middle) 531 SOUTH SPRING STREET					3. Date of Earliest Transaction (Month/Day/Year) 02/12/2019								CEO, Covance Drug Development							
							4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Indi									dividual or Joint/Group Filing (Check Applicable				
(Street)	IGTON N	ON NC 27215										Lir	Line) X Form filed by One Reporting Person							
					_								Form filed by More than One Reporting Person							
(City)	(S	State)	(Zip)											r Glauli						
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Da			Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			Beneficially Owned Foll	,	6. Owner Form: D (D) or Ir (I) (Insti	Direct Ir ndirect B r. 4) C	Nature of lirect neficial vnership			
								Code	v	Amount	(A) or (D)	Price	Reported Transaction (Instr. 3 and		(In		nstr. 4)			
Common	Common Stock			02/12/2019)		M		1,463	A	(1)	16,25	55	D				
Common Stock			02/12/2019		.9			F ⁽²⁾		654	D	\$146.5	9 15,60)1	D					
Common Stock													40	40		I r	evocable ust			
Common Stock													80 ⁽³	i)	I		y revocable ust			
			Table II								osed of, o			Owned	<u> </u>			1		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	emed 4. on Date, Tran		s. S. Number Derivative Securities Acquired (or Dispose of (D) (Inst 4 and 5)		per of ve es ed (A) osed nstr. 3,		Exerc			nd Amour ties ng e Securit	Derivative Security	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amour or Number of Shares	er	(Instr. 4)					
Restricted Stock Unit	(1)	02/12/2019			M			1,463	(4	1)	(4)	Common Stock	1,463	3 \$0	16,91	11 ⁽⁵⁾	D			
Restricted Stock Unit	(1)	02/12/2019			A		5,300		(6)		(6)	Common Stock	5,300	\$0	22,21	22,211 ⁽⁵⁾				
Non- qualified Stock	\$146.59	02/12/2019			A		21,800		02/12/2	2020 ⁽⁸⁾	02/11/2029	Common Stock	21,80	0 \$0	21,8	800	D			

Explanation of Responses:

- 1. Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- 2. Stock withholding to satisfy tax withholding obligations.
- 3. The reporting person is not a trustee of the irrevocable trust and disclaims beneficial ownership of the shares.
- 4. The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on 2/12/19.
- 5. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
- 6. The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2020.
- 7. Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
- 8. The option vests in three equal installments beginning on the date reflected in this column.

/s/ Sandra D. van der Vaart, Attorney-in-Fact for John D.

02/14/2019

Ratliff

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.